Clinical Trial Detail

NCT ID NCT03012230
Title Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Mayo Clinic
Indications

triple-receptor negative breast cancer

Therapies

Pembrolizumab + Ruxolitinib

Age Groups: adult senior

No variant requirements are available.